The facility is intended to target the global markets with antibody based drugs including Herceptin biosimilar.
Dong-A and Japanese company, Meiji Seika Pharma signed an agreement to develop biosimilar prodcuts.
Dong-A and Meiji will first construct a biosimilar cGMP plant in the Songdo International Business District, and add on facilities to conduct research, develop, manufacture and commercialize biosimilar products in global markets.
Dong-A also plans additional investment in Songdo to export biopharmaceutical products such as PEG-G-CSF for neutropenia, interferon beta, and diabetes treatments in Dong-A’s current pipeline.